CGEM News and Press, Cullinan Oncology Inc. From 05/09/24

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Cullinan Therapeutics Inc. (CGEM) is expected to report $-0.9 for Q1 2024

2024-04-29 07:58:23 ET More on Cullinan Oncology Amgen’s Blincyto data send Cullinan higher Cullinan Therapeutics expands into autoimmune diseases Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings data for Cullinan Oncology ...

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. “I am ...

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...

2024-04-26 13:09:16 ET Read the full article on Seeking Alpha For further details see: PEGY, CGEM and IFBD among mid-day movers

Cullinan Oncology, Inc. (NASDAQ: CGEM) is one of today's top gainers. The company's shares have moved 30.12% on the day to $25.05. Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the...

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be pre...

2024-04-16 14:00:02 ET Edward White from H.C. Wainwright issued a price target of $29.00 for CGEM on 2024-04-16 11:53:00. The adjusted price target was set to $29.00. At the time of the announcement, CGEM was trading at $17.625. The overall price target consensus is at $...

Shares of Cullinan Oncology, Inc. (NASDAQ: CGEM) traded at a new 52-week high today and are currently trading at $19.91. So far today, approximately 771.44k shares have been exchanged, as compared to an average 30-day volume of 277.78k shares. Cullinan Oncology Inc., a biopharmaceutical compa...